Germany Dividends

2025 Dividend Portfolio Review: The Good, The Bad and The Dollar

In our 2025 dividend portfolio annual report, we break down our savings rate, organic dividend growth and yield on cost. Discover how dollar headwinds impacted our results and how we strengthened portfolio quality while marching toward financial freedom.

(europeandgi.com)
💬 🔗
Author
The Investor 04-19-26
Evonik announced a new, more flexible dividend policy while confirming it met its earnings guidance for 2025. Starting with the 2026 financial year, Evonik will target an annual shareholder distribution of 40–60% of adjusted net income, replacing the previous fixed approach. As a transition, the company plans to pay a dividend of €1.00 per share for 2025, down from €1.17 previously, implying a dividend yield of about 7%.

Evonik reported adjusted EBITDA of €1.874 billion for 2025, in line with guidance, despite sales declining around 7% year on year to €14.1 billion. Strong cash generation supported a free cash flow of €695 million and a cash conversion rate at the top of the target range. Net income rose to €265 million.

For 2026, Evonik expects adjusted EBITDA between €1.7 and €2.0 billion, citing a challenging economic environment. Management said the new dividend policy aims to balance shareholder returns with financial flexibility, investment capacity, and further deleveraging.
💬 🔗
Author
European Investor 02-08-26
Pfizer Declares $0.43 Quarterly Dividend for Q1 2026

Pfizer’s board approved a first-quarter 2026 cash dividend of $0.43 per share, payable on March 6, 2026, to shareholders of record as of January 23, 2026, marking the company’s 349th consecutive quarterly dividend.

Source: Business Wire
💬 🔗
Author
European Investor 12-14-25